Cargando…

ctDNA facilitated the diagnosis of a patient with synchronous urothelial carcinoma and non-small cell lung cancer: case report

The diagnosis and treatment for multiple primary cancers have been a great challenge in clinical practice. Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA that circulates in the blood. Herein we report a case that ctDNA facilitated the diagnosis of synchronous urothelial carcinoma (UC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Chengyuan, Dai, Nan, Xu, Mingfang, Luo, Hao, Feng, Yan, Zhang, Min, Chen, Rongrong, Wang, Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661894/ https://www.ncbi.nlm.nih.gov/pubmed/33209903 http://dx.doi.org/10.21037/atm-20-6552

Ejemplares similares

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

The feasibility of using mutation detection in ctDNA to assess tumor dynamics
por: Yi, Xin, et al.
Publicado: (2017)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma—Literature Review
por: Kopystecka, Agnieszka, et al.
Publicado: (2023)

Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis
por: Zheng, Yang, et al.
Publicado: (2021)

Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer
por: Zhu, Chennianci, et al.
Publicado: (2020)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients
por: Provencio, Mariano, et al.
Publicado: (2017)

Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer
por: Gobbini, Elisa, et al.
Publicado: (2020)

Investigate the application of postoperative ctDNA-based molecular residual disease detection in monitoring tumor recurrence in patients with non-small cell lung cancer——A retrospective study of ctDNA
por: Zhang, Xuefei, et al.
Publicado: (2023)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer
por: Shields, Misty Dawn, et al.
Publicado: (2022)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

Correction to: Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

Comparative study on the mutation spectrum of tissue DNA and blood ctDNA in patients with non-small cell lung cancer
por: Zhang, Meichun, et al.
Publicado: (2022)

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
por: Khatami, Fatemeh, et al.
Publicado: (2018)

Detection of ctDNA in the plasma of patients with papillary thyroid carcinoma
por: Li, Huiqiang, et al.
Publicado: (2019)

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
por: Abbosh, Christopher, et al.
Publicado: (2021)

The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
por: Ding, Yubo, et al.
Publicado: (2022)

Current and Future Clinical Applications of ctDNA in Immuno-Oncology
por: Stadler, Julia-Christina, et al.
Publicado: (2022)

Regulatory implications of ctDNA in immuno-oncology for solid tumors
por: Vellanki, Paz J, et al.
Publicado: (2023)

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review
por: Wang, Wenwen, et al.
Publicado: (2023)

Phylogenetic ctDNA analysis depicts early stage lung cancer evolution
por: Abbosh, Christopher, et al.
Publicado: (2017)

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
por: Abbosh, Christopher, et al.
Publicado: (2023)

Evaluating the cerebrospinal fluid ctDNA detection by next-generation sequencing in the diagnosis of meningeal Carcinomatosis
por: Zhao, Yue, et al.
Publicado: (2019)

ctDNA as a novel and promising approach for cancer diagnosis: a focus on hepatocellular carcinoma
por: Biglari, Negin, et al.
Publicado: (2023)

Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancer
por: Metzenmacher, Martin, et al.
Publicado: (2021)

Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer
por: Semenkovich, Nicholas P., et al.
Publicado: (2023)

Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer
por: Semenkovich, Nicholas P., et al.
Publicado: (2023)

The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients
por: Yang, Yin, et al.
Publicado: (2022)

The association of blood ctDNA levels to mutations of marker genes in colorectal cancer
por: Bai, Fei, et al.
Publicado: (2023)

The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues
por: Yang, Nong, et al.
Publicado: (2018)

The Pathological Features of Colorectal Cancer Determine the Detection Performance on Blood ctDNA
por: He, Na, et al.
Publicado: (2018)

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer
por: Todenhöfer, Tilman, et al.
Publicado: (2018)

ctDNA Detection Based on DNA Clutch Probes and Strand Exchange Mechanism
por: Chang, Huan, et al.
Publicado: (2018)

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
por: Anagnostou, Valsamo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gmk47vv3eohog4j2gntig9vnbq